Skip to main content
All lobbying filings

EDWARDS LIFESCIENCES, LLC

Lobbying for EDWARDS LIFESCIENCES LLC

 Filing 3rd Quarter - Report
3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $280,000.00 expenses · posted Oct 20, 2025

Official filing document

 Bills named in this filing 2
  • HR 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
 Lobbying activity 4
Taxation/Internal Revenue Code

Corporate Tax Reform Proposals

Trade (domestic/foreign)

Tariffs Japan Reimbursement of Medical Devices

Health Issues

Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials

Medicare/Medicaid

CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem